Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 160 |
Synonyms | |
Therapy Description |
AMG 160 is a bi-specific T-cell engager (BiTE) antibody that binds to PSMA and CD3, potentially resulting in enhanced T-cell response and antitumor activity against PSMA-expressing tumor cells (PMID: 33504551). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 160 | HLE-BiTE AMG 160|AMG-160|AMG160|Acapatamab | PSMA Antibody 20 | AMG 160 is a bi-specific T-cell engager (BiTE) antibody that binds to PSMA and CD3, potentially resulting in enhanced T-cell response and antitumor activity against PSMA-expressing tumor cells (PMID: 33504551). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03792841 | Phase I | AMG 160 + Pembrolizumab AMG 160 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC | Completed | USA | NLD | FRA | CAN | BEL | AUT | AUS | 3 |
NCT04822298 | Phase I | AMG 160 | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | Terminated | USA | AUT | AUS | 0 |